Literature DB >> 9181631

Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients.

M Deuschle1, S Härtter, C Hiemke, H Standhardt, I Heuser.   

Abstract

Little information exists on the concentrations of antidepressants and their metabolites in CSF. We measured plasma and CSF levels of trans-doxepin (trans-DOX) and DOX metabolites in 12 depressed patients treated with DOX (250 mg/day) for 6 days. Spinal taps and blood samples were taken on day 7, 10 h after drug administration. Trans-DOX, cis-desmethyldoxepin (cis-DM-DOX), trans-desmethyldoxepin (trans-DM-DOX) and di-desmethyldoxepin (DDM-DOX) were analyzed in CSF and plasma samples by HPLC with column-switching. Although DOX was given as a mixture of 85% trans-DOX and 15% of the pharmacologically more active cis-DOX, we found similar amounts of cis-DM-DOX and trans-DM-DOX in plasma (59.8 +/- 45.1 versus 72.0 +/- 60.0 ng/ml; NS), suggesting that isomerization of DOX had taken place. Trans-DOX and DOX metabolites could be detected in CSF of most patients. Relatively low CSF concentrations of the active metabolite cis-DM-DOX were measured. Clinical efficacy, as assessed by HAMD scores, was not significantly related to plasma or CSF concentrations of trans-DOX or its metabolites. Trans-DOX and DOX metabolites were distributed differently between plasma and CSF. It is concluded that isomerization of DOX is not only relevant for neuronal uptake inhibition, but also for the transport of the metabolites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181631     DOI: 10.1007/s002130050260

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  3 in total

Review 1.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Doxepin concentrations in plasma and cerebrospinal fluid.

Authors:  Robert Schomburg; Daniela Remane; Klaus Fassbender; Hans H Maurer; Jörg Spiegel
Journal:  J Neural Transm (Vienna)       Date:  2011-02-25       Impact factor: 3.575

3.  The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

Authors:  Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.